Business Description
Eloxx Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US29014R2022
Total Employee Number:
7Description
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 4.79 | |||||
Equity-to-Asset | -2.26 | |||||
Debt-to-Equity | -0.08 | |||||
Debt-to-EBITDA | -0.2 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 70.4 | |||||
3-Year EPS without NRI Growth Rate | 67 | |||||
3-Year FCF Growth Rate | 67.3 | |||||
3-Year Book Growth Rate | 20.3 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 52.84 | |||||
9-Day RSI | 58.72 | |||||
14-Day RSI | 60.96 | |||||
3-1 Month Momentum % | 357.92 | |||||
6-1 Month Momentum % | 369900 | |||||
12-1 Month Momentum % | 369900 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.31 | |||||
Quick Ratio | 0.31 | |||||
Cash Ratio | 0.28 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -30.2 | |||||
Shareholder Yield % | 13 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROA % | -145.4 | |||||
ROIC % | -39.28 | |||||
3-Year ROIIC % | -513.41 | |||||
ROC (Joel Greenblatt) % | -3015.85 | |||||
Moat Score | 4 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-EBIT | -8.88 | |||||
EV-to-EBITDA | -8.88 | |||||
EV-to-Forward-Revenue | 6.37 | |||||
EV-to-FCF | -6.94 | |||||
Earnings Yield (Greenblatt) % | -11.26 | |||||
FCF Yield % | -13.27 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ELOX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Eloxx Pharmaceuticals Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -5.39 | ||
| Beta | -1283.1622 | ||
| 3-Year Sharpe Ratio | 0.58 | ||
| 3-Year Sortino Ratio | 284.74 | ||
| Volatility % | 80679.39 | ||
| 14-Day RSI | 60.96 | ||
| 14-Day ATR ($) | 2.535198 | ||
| 20-Day SMA ($) | 10.741755 | ||
| 12-1 Month Momentum % | 369900 | ||
| 52-Week Range ($) | 0.00011 - 17.5 | ||
| Shares Outstanding (Mil) | 3.44 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Eloxx Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Eloxx Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 135 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 44 days | ||
| General meeting for 2025 | 2026-06-29 | 12.05 (+13.42%) | ||
| 0.0909091:1 Stock Split | 2026-06-01 | 4.07 (+2.78%) | ||
| First quarter earnings results for 2026 | 2026-05-05 | 1.98 (-0.77%) | ||
| Annual report for 2025 | 2026-03-17 | 0.00 (+0.00%) | ||
| 0.025:1 Stock Split | 2022-12-02 | 42.15 (-18.12%) | ||
| 0.05:1 Stock Split | 2017-12-20 | 2,640.00 (-6.54%) | ||
| 0.01:1 Stock Split | 2013-10-21 | 26,839.14 (-9.76%) | ||
| 2:1 Stock Split | 1999-10-25 | 3,916,046.99 (-3.78%) |
Show
Entries
Eloxx Pharmaceuticals Inc Frequently Asked Questions
What is Eloxx Pharmaceuticals Inc(ELOX)'s stock price today?
The current price of ELOX is $13.88. The 52 week high of ELOX is $17.50 and 52 week low is $0.00.
When is next earnings date of Eloxx Pharmaceuticals Inc(ELOX)?
The next earnings date of Eloxx Pharmaceuticals Inc(ELOX) is 2026-08-14 Est..
Does Eloxx Pharmaceuticals Inc(ELOX) pay dividends? If so, how much?
Eloxx Pharmaceuticals Inc(ELOX) does not pay dividend.
Guru Commentaries on NAS:ELOX
No articles.
Press Release
Articles on Eloxx Pharmaceuticals Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers